<DOC>
	<DOCNO>NCT01342042</DOCNO>
	<brief_summary>This research randomize , control trial . 36 Chinese subject Type 2 Diabetes Mellitus take part trial . Subjects randomly enter one three group , administration daily twice , period 84 day treatment . Subjects hospital pharmacokinetic study 1 d~ 8d , 30 ( necessary ) 84 , 9 ~ 83 outpatient follow-up .</brief_summary>
	<brief_title>The Safety , Preliminary Pharmacodynamics Pharmacokinetics Study rExenatide-4 Chinese Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>1 . 18 ~ 75 year T2DM China ; 2 . HbA1c 7 % 13 % ; 3. negative pregnancy test female , subject family plan test end within 3 month . 1 . HBsAg , HCV , HIV syphilis test positive ; 2. time FBG &lt; 6.1 &gt; 14.0 mmol / L morning ; 3 . Renal function : eGFR &lt; 60 mL / min ; 4 . TG &gt; 5mmol / L ; 5 . Pancreatitis , cholecystitis , gallstone gastrointestinal disease ; 6 . Ischemic heart disease , heart failure , stroke peripheral vascular disease ; 7 . Pregnancy breastfeed woman ; 8 . Patients require insulin treatment ; 9 . Have medical history hypoglycemia ; 10 . Have clear history allergic patient ; 11 . Patients addict alcohol tobacco .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>diabetes</keyword>
	<keyword>rRE-4</keyword>
	<keyword>exenatide</keyword>
	<keyword>metformin</keyword>
	<keyword>CSPC ZhongQi</keyword>
</DOC>